Wang W, Cooper C. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression. World J Cardiol 2025; 17(1): 102467 [PMID: 39866212 DOI: 10.4330/wjc.v17.i1.102467]
Corresponding Author of This Article
Wei Wang, Chronic Disease and Health Management Research Center, Geriatric Hospital of Nanjing Medical University, No. 30 Luojia Road, Nanjing 210024, Jiangsu Province, China. wwtxdy@163.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jan 26, 2025; 17(1): 102467 Published online Jan 26, 2025. doi: 10.4330/wjc.v17.i1.102467
Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression
Wei Wang, Charlie Cooper
Wei Wang, Charlie Cooper, Chronic Disease and Health Management Research Center, Geriatric Hospital of Nanjing Medical University, Nanjing 210024, Jiangsu Province, China
Author contributions: Wang W designed the editorial and wrote the manuscript; Cooper C edited the manuscript; all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Wang, Chronic Disease and Health Management Research Center, Geriatric Hospital of Nanjing Medical University, No. 30 Luojia Road, Nanjing 210024, Jiangsu Province, China. wwtxdy@163.com
Received: October 21, 2024 Revised: December 2, 2024 Accepted: December 13, 2024 Published online: January 26, 2025 Processing time: 94 Days and 22.3 Hours
Core Tip
Core Tip: Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM), both components of metabolic syndrome, are increasingly recognized for their synergistic impact on cardiovascular health. The intertwined relationship between these conditions amplifies the risk of cardiovascular disease, highlighting the need for integrated management strategies to mitigate this dual threat. Through a comprehensive evaluation of Cernea et al’s study on the combination of MASLD and T2DM in promoting cardiac dysfunction, this editorial provides a comprehensive review of the current research on MASLD and cardiovascular disease, a discussion of the progress made in this field, and the potential directions for future research.
